Thalidomide: a remarkable comeback

Bibliography

• TSENG S, PAK G, WASHENIK K et al.: Rediscoveringthalidomide: a review of its mechanism of action, side effects and potential uses. J. Am. Acad. Dermatol. (1996) 35:969–979.
   PubMed Web of Science ®Google Scholar
• ERIKSSON T, BJORKMAN S, ROTH B et al.: Hydroxylatedmetabolites of thalidomide: formation in vitro and in vivo in man. J. Pharm. Pharmacol. (1998) 50:1409–1416.
   PubMed Web of Science ®Google Scholar
• MCFADYEN RE: Thalidomide in America: a brush with tragedy. Clio Medica. (1976) 11(2):79–93.
   PubMedGoogle Scholar
• LENZ W: Thalidomide and congenital abnormalities. Lancet (1962) 1:45.
   Web of Science ®Google Scholar
• •The first report of thalidomide's teratogenicity.
   Google Scholar
• EISEN T, BOSHPFF C, VAUGHAN MM et al.: Anti-angiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalido-mide: a Phase II study. Proceedings of ASCO. (1998) 17:441a. Abstract 1699.
   Google Scholar
• LASAGNA L: Congress, the FDA and new drug develop-ment: before and after 1962. Persp. Biol. Med. (1989) 32(3):322–343.
   PubMed Web of Science ®Google Scholar
• SHESKIN J: Thalidomide in the treatment of leprareactions. Clin. Pharmacol. Ther. (1965) 6:303–306.
   PubMed Web of Science ®Google Scholar
• •The first report of thalidomide's clinical potential as an immunomodulator. Exp. Opin. Pharmacother. (2000) 1(4)
   Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY R et al.: Thalidomide selectively inhibits tumour necrosis factor a produc-tion by stimulated human monocytes. J. Exp. Med. (1991) 173:699–703.
   PubMed Web of Science ®Google Scholar
• •A study that reported thalidomide's anti-TNF-a effect.
   Google Scholar
• PETERSON PK, HU S, SHENG WS et al.: Thalidomide inhibits tumour necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microg,lial cells. J. Infect. Dis. (1995) 172:1137–1140.
   PubMed Web of Science ®Google Scholar
• MAKONKAWKEYOON S, LIMSON-POBRE RNR, MOREIRAAL, SCHAUF V, KAPLAN G: Thalidomide inhibits replica-tion of human immunodeficiency virus Type 1. Proc. Natl. Acad. Sci. USA (1993) 90:5974–5978.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, MORIERIA AL, SARNO EN et al.: Prolongedtreatment with recombinant interferon y induces erythema nodosum leprosum in lepromatous leprosy patients. J. Exp. Med. (1992) 175:1729–1737.
   PubMed Web of Science ®Google Scholar
• TRAMONTANA JM, UTAIPAT U, MOOLOY A et al.: Thalidomide treatment reduces tumour necrosis factor a production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. (1995) 1:384–397.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, KAPLAN G, MIRANDA A et al.: The influence of thalidomide on the clinical and immuno-logic manifestation of erythma nodosum leprosum. J. Infect. Dis. (1993) 168:408–414.
   PubMed Web of Science ®Google Scholar
• KLAUSNER JD, MAKONKAWKEYOON S, AKARASEWI P etal.: The effect of thalidomide on the pathogenesis of human immunodeficiency virus Type 1 and M. tuberculosis infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1996) 11:247–257.
   Google Scholar
• SHIBATA Y, SASAKI H, HASHIMOTO Y, IWASAKI S: Tumor necrosis factor-a production enhancers with a phenylphthalimide skeleton. Biochem Biophys Res. Commun. (1994) 205:1992–1997.
   PubMed Web of Science ®Google Scholar
• D'AMATO RJ, LOUGHMAN MS, FLYNN E et al.: Thalido- mide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• •A study reporting thalidomide's anti-angiogene activity.
   Google Scholar
• BAUER KS, DIXON SC, FIGG WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. (1998) 55:1827–1834.
   PubMed Web of Science ®Google Scholar
• MORIERA AL, SAMPAIO EP, ZMUIDZINAS A et al.: Thalidomide exerts its inhibitory action on inhibits tumour necrosis factor a by enhancing mRNA degradation. J. Exp. Med. (1993) 177:1675–1680.
   PubMed Web of Science ®Google Scholar
• •A study that reported thalidomide's mechanism of TNF-a inhibition.
   Google Scholar
• JACOBSON JM, GREENSPAN JS, SPRITZLER J et al.: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N. Engl. J Med. (1997) 336:1487–1493.
   PubMed Web of Science ®Google Scholar
• •A study definitively establishing thalidomide's effectiveness in treating oral aphthous ulcers in HIV-infected patients. It showed no systemic anti-TNF-a effect of thalidomide and an enhancing effect of thalidomide on HIV viraemia.
   Google Scholar
• JACOBSON JM, SPRITZLER J, FOX L: Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J. Infect. Dis. (1999) 180(1):61–67.
   PubMed Web of Science ®Google Scholar
• •Report of a study establishing thalidomide's effectiveness in treating oesophageal aphthous ulcers in HIV-infected patients.
   Google Scholar
• MCHUGH SM, RIFKIN IR, DEIGHTON J et al.: The immunosuppressive drug thalidomide induces T helper cell Type 2 (Th2) and concomitantly inhibits Thl cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol. (1995) 99:160–167.
   PubMed Web of Science ®Google Scholar
• HASLETT PA, CORRAL LG, ALVERT M, KAPLAN G: Thalidomide costimulates primary human T lympho-cytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J. Exp. Med. (1998) 187:1885–1892.
   PubMed Web of Science ®Google Scholar
• HASLETT P, HEMPSTEAD M, SEIDMAN C et al.: The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res. Hum. Retroviruses. (1997) 13:1047–1054.
   PubMed Web of Science ®Google Scholar
• SHANNON EJ, SANDOVAL F: Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, staphylococcal enterotoxin A and purified protein derivative. Immunopharmacology (1995) 31:109–116.
   PubMed Web of Science ®Google Scholar
• MOLLER DR, WYSOCKA M, GREENLEE BM et al.: Inhibi-tion of IL-12 production by thalidomide. J. Immunol. (1997) 159:5157–5161.
   PubMed Web of Science ®Google Scholar
• FAURE M, THIVOLET J, GAUCHERAND M: Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch. Dermatol. Res. (1980) 269:275–280.
   PubMed Web of Science ®Google Scholar
• ZWINGENBERGER K, WENDT S: Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J. Inflamm. (1995–96) 46:177–211.
   Google Scholar
• •A good review of thalidomide's immunomodulation activities.
   Google Scholar
• NOGUEIRA AC, GRAFE M, NEUBERT R: Effect of thalido-mide and some derivatives on the adhesion of lympho-cytes to endothelial cells. Naunyn-Schmiedebergs Arch Pharmacol. (1995) 351(Suppl.):R130.
   Google Scholar
• GEITZ H, HANDT S, ZWINGENBERGER K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immuno-pharmacology (1996) 31:213–221.
   PubMed Web of Science ®Google Scholar
• SCHEFFLER MR, COLBURN W, KOOK KA et al.: Thalido-mide does not alter estrogen-progesterone hormone single dose pharmacokinetics. Clin. Pharmacol. Ther. (1999) 65:597–602.
   Web of Science ®Google Scholar
• CHEN TL, VOGELSANG GB, PETTY BG et al.: Plasmapharmacokinetics and urinary excretion of thalido-mide after oral dosing in healthy male volunteers. Drug Metab. Dispos. (1989) 17:402–405.
   PubMed Web of Science ®Google Scholar
• NOORMOHAMED F, YOULE MS, HIGGS CJ et al Pharma- cokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. AIDS Res. Hum. Retroviruses (1999) 15:1047–1052.
   Google Scholar
• TRAPNELL CB, DONAUE SR, COLLINS JM et al.: Thalido-mide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Gun. Pharmacol. Ther. (1998) 64:597–602.
   PubMed Web of Science ®Google Scholar
• PISCITELLI SC, FIGG WD, HAHN B et al.: Single dosepharmacokinetics of thalidomide in human immuno-deficiency virus-infected patients. Antimicrob. Agents Chemother. 1997 41:2797–2799.
   PubMed Web of Science ®Google Scholar
• FIGG WD, RAJE S, BAUER KS et al.: Pharmacokinetics of thalidomide in an elderly prostate cancer population. J. Pharm. Sci. (1999) 88:121–125.
   PubMed Web of Science ®Google Scholar
• ERIKKSON T, BJORKMAN S, ROTH B et al.: Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality (1998) 10:223–228.
   PubMed Web of Science ®Google Scholar
• SCHULER U, EHNINGER G: Thalidomide: rationale for renewed use in immunological disorders. Drug. Saf (1995) 12:364–369.
   PubMed Web of Science ®Google Scholar
• GORDON GB, SPIELBERG SP, BLAKE DA et al.: Thalido-mide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. USA (1981) 78:2545–2548.
   PubMed Web of Science ®Google Scholar
• GUNZLER V: Thalidomide in human immunodefi-ciency virus (HIV) patients. A review of safety consid-erations. Drug Saf (1992) 7:116–134.
   PubMed Web of Science ®Google Scholar
• •A good thalidomide review.
   Google Scholar
• BHARGAVA P, MAL KULDEEP C, MATHUR NK: Erythema nodosum leprosum in subgroups of lepromatous leprosy. Lepr. Rev. (1998) 68:373–385.
   Web of Science ®Google Scholar
• MEYERSON MS: Erythema nodosum leprosum. Int. J. Dermatol. (1996) 35:389–392.
   PubMed Web of Science ®Google Scholar
• WILLCOX ML: The impact of multiple drug therapy on leprosy disabilities. Lepr. Rev. (1997) 68:350–366.
   PubMed Web of Science ®Google Scholar
• PARTIDA-SANCHEZ S, FAVILA-CASTILLO L, PEDRAZA-SANCHEZ S et al.: IgG antibody subclasses, tumour necrosis factor and IFNI levels in patients with Type II lepra reaction on thalidomide treatment. Int. Arch. Allergy Immunol. (1998) 116:60–66.
   PubMed Web of Science ®Google Scholar
• SHESKIN J, CONVIT J: Results of a double blind study of the influence of thalidomide on the lepra reaction. Int. J. Lept. Other Mycobact. Dis. (1969) 37:135–146.
   PubMedGoogle Scholar
• •Report of a controlled study establishing thalidomide's effectiveness in treating ENL.
   Google Scholar
• IYER CG, LANGUILLON J, RAMANUJAM K et al.: WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. World Health Organ. (1971) 45:719–732.
   PubMed Web of Science ®Google Scholar
• CELGENE (WARREN NJ): Thalidomide® (thalidomide)capsules prescribing information (1998).
   Google Scholar
• SARNO EN, GRAU GE, VIEIRA LMM, NERY JA: Serumlevels of tumour necrosis factor-alpha and interleukin 10 during leprosy reactional states. Clin. Exp. Immunol. (1991) 84:103–108.
   PubMed Web of Science ®Google Scholar
• YOULE M, CLARBOUR J, FARTHING C et al.: Treatment ofresistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br. Med. J. (1989) 298:432.
   PubMed Web of Science ®Google Scholar
• GORIN I, VILETTE B, GEHANNO P, ESCANDE JP: Thalido-mide in hyperalgic pharyngeal ulceration of AIDS. Lancet (1990) 335:1343.
   PubMedGoogle Scholar
• GEORGHIOU PR, KEMP RJ: HIV-associated esophagealulcers treated with thalidomide. Med. J. Aust. (1990) 152:382–383.
   PubMed Web of Science ®Google Scholar
• PATERSON DL, GEORGHIOU PR, ALLWORTH AM, KEMPRJ: Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis. (1995) 20:250–254.
   PubMed Web of Science ®Google Scholar
• MASCARO JM, LECHA M, TORRAS H: Thalidomide in thetreatment of recurrent, necrotic and giant mucocuta-neous aphthae and aphthosis. Arch. Dermatol. (1979) 115:636–637.
   PubMed Web of Science ®Google Scholar
• JENKINS JS, POWELL RJ, ALLEN BR et al.: Thalidomide insevere orogenital ulceration. Lancet(1984) 2:1424–1426.
   PubMed Web of Science ®Google Scholar
• GRINSPAN D: Significant response of oral aphthosis tothalidomide treatment. J. Am. Acad. Dermatol. (1985) 12:85–90.
   PubMed Web of Science ®Google Scholar
• REVUZ J, GUILLAUME J-C, JANIER M et al.: Crossoverstudy of thalidomide vs. placebo in severe recurrent aphthous stomatitis. Arch. Dermatol. (1990) 126:923–927.
   Google Scholar
• HAMURYUDAN V, MAT GEM, SAIP SEBAHATTAIN et al.:Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1998) 128:443–450.
   PubMed Web of Science ®Google Scholar
• JORIZZO JL, SCHMALSTIEG FC, SOLOMON AR, JR. et al.:Thalidomide effects in Behcet' s syndrome and pustular vasculitis. Arch. Intern. Med. (1986) 146:878–881.
   Google Scholar
• GRUNFELD C, FEINGOLD KR: Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl. J. Med. (1992) 327:329–337.
   PubMed Web of Science ®Google Scholar
• REYES-TERAN G, SIERRA-MADERO JG et al.: Effects ifthalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS (1996) 10:1501–1507.
   PubMed Web of Science ®Google Scholar
• KAPLAN G, SCHAMBELAN M, GOTTLIEB M et al.: Thalido-mide reverses cachexia in HIV-wasting syndrome. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1998). Abstract 476.
   Google Scholar
• SHARPSTONE DR, ROWBOTTOM AW, NELSON NM, GAZZARD B: The treatment of microsporidial diarrhea with thalidomide. AIDS (1995) 9:658–659.
   PubMed Web of Science ®Google Scholar
• QUINONES F, SIERRA-MADERO J, CALVA-MERCADO JJ,RUIZ-PALACIOS GM: Thalidomide in patients with HIV infection and chronic diarrhoea: double blind placebo controlled clinical trial. 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, USA (1997). Abstract 682. Exp. Opin. Pharmacother. (2000) 1(4)
   Google Scholar
• KAPLAN G, FREEDMAN VH: The role of cytokines in theimmune response to tuberculosis. Res. Immunol. (1996) 147:565–572.
   PubMedGoogle Scholar
• KAPLAN G: Thalidomide treatment reduces TNF-a production and enhances weight gain in patients with pulmonary tuberculosis. J. Cell. Biochem. (1995) 57(Suppl. 19B):61. Abstract B3–018.
   Google Scholar
• SAURAT JH, CAMENZIND M, HELG C, CHAPUIS B: Thalidomide for graft-versus-host disease after bone marrow transplantation [letter]. Lancet. (1988) 1:359.
   PubMed Web of Science ®Google Scholar
• LIM SH, MCWHANNELL A. VORA AJ, BOUGHTON BJ: Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation [letter]. Lancet. (1988) 1:117.
   PubMed Web of Science ®Google Scholar
• HENEY D, NORFOLK DR, WHEELDON J et al.: Thalido-mide treatment for chronic graft-versus-host disease. Br. J. Haematol. (1991) 78:23-27. VOGELSANG GB, FARMER ER, HESS AD et al.: Thalido-mide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. (1992) 326:1055-1058. An uncontrolled study reporting thalidomide's effectiveness in treating chronic GVHD. CHAO NJ, PARKER PM, NILAN JC et al.: Paradoxical effect of thalidomide prophylaxis on chronic graft-versus-host disease. Biol. Blood Marrow Transplant. (1996) 2:86–92.
   Google Scholar
• VAN DEN BROEK H: Treatment of prurigo nodularis with thalidomide. Arch. Dermatol. (1980) 116:571–572.
   PubMedGoogle Scholar
• FERRANDIZ C, CARRASCOSA JM, JUST M et al.: Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. Dermatology (1997) 195:359–361.
   PubMed Web of Science ®Google Scholar
• SHESKIN J: Zur therapie der prurigo nodularis hyde mit thalidomid. Der Hautarzt. (1975) 26:215–217.
   PubMedGoogle Scholar
• WINKELMANN RK, CONNOLLY SM, DOYLE JA, PADILHA- GONCALVES A: Thalidomide treatment of prurigo nodularis. Acta. Derm. Venereol. (1984) 64:412–417.
   PubMed Web of Science ®Google Scholar
• JOHNKE H, ZACHARIAE H: Thalidomide treatment of prurigo nodularis Ugeskr. Laeger. (1993) 155:3028–3030.
   PubMedGoogle Scholar
• KNOP J, BONSMANN G, HAPPLE R et al.: Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br. J. Rheumatol. (1983) 108:461–466.
   Google Scholar
• STEVENS RJ, ANDUJAR C, EDWARDS CJ et al.: Thalido- mide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br.J.Rheumatol. (1997) 36:353–359.
   PubMedGoogle Scholar
• GUTIERREZ-RODRIGUEZ 0, STARUSTA-BACAL P, GUTIERREZ-MONTES 0: Treatment of rheumatoid arthritis - the thalidomide experience. J. Rheumatol. (1989) 16:158–163.
   PubMed Web of Science ®Google Scholar
• KEESAL N, WASSERMAN MJ, BOOKMAN A et al.: Thalido- mide in the treatment of refractory rheumatoid arthritis. J. Rheumatol. (1999) 26(10:2344–2347.
   PubMed Web of Science ®Google Scholar
• STAMBE C, WICKS IP: TNF-alpha and response of treatment-resistant adult-onset Still's disease to thalidomide. Lancet (1998) 352:544–545.
   PubMed Web of Science ®Google Scholar
• BREBAN M, GOMBERT B, AMOR B, DOUGADOS M: Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum. (1999) 42(3):580–581.
   PubMed Web of Science ®Google Scholar
• EHRENPREIS ED, KAIS SV, COHEN LB, COHEN RD AND HAMMER SB: Thalidomide Therapy for Patients With Refractory Crohn's Disease: An Open-Label Trial. Gastroenterology (1999) 117:1271–77.
   PubMed Web of Science ®Google Scholar
• VASILIAUKIS EA, KAM LY, ABREU-MARTIN MT et al.: An Open-Label Pilot Study of Low Dose Thalidomide in Chronically Active, Steroid-Dependent Crohn's Disease. Gastroenterology (1999) 117:1278–87.
   PubMed Web of Science ®Google Scholar
• ROUSSEAU L, BEYLOT-BARRY M, DOUTRE MS et al.: Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch. Dermatol. (1998) 134:1045–1046.
   PubMedGoogle Scholar
• WATERS MF, LAING AB, AMBIKAPATHY A et al.: Treatment of ulcerative colitis with thalidomide. Br. Med. J. (1979) 1:792.
   PubMed Web of Science ®Google Scholar
• SOLER RA, HOWARD M, BRINK NS et al.: Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin. Infect. Dis. (1996) 23:501–503.
   PubMed Web of Science ®Google Scholar
• WELLER L, LITTLE R, QYVILL K et al.: Preliminary results of Phase II study of oral thalidomide in patients with HIV infection and Kaposis's sarcoma (KS). J. Acquir. Immune Defic. Synd. Hum. Retrovirol. (1997) 14:A21. Abstract 20.
   Google Scholar
• BOWER M, HOWARD M, GRACIE F et al.: A Phase II study of thalidomide for Kaposi's sarcoma: activity and correlation with KSHV DNA load. J. Acquir. Immune Defic. Synd. Hum. Retrovirol. (1997) 14:A35. Abstract 76.
   Google Scholar
• SEEMA SINGHAL, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341:1565–1571.
   PubMed Web of Science ®Google Scholar
• •A report of an uncontrolled study showing thalidomide's activity in the therapy of treatment-resistant multiple myeloma.
   Google Scholar
• NGUYEN M, TRAN C, BARKY S et al.: Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies. Int. J. Oncol. (1997) 10:965–969.
   PubMed Web of Science ®Google Scholar
• SMITHELLS RW, NEWMAN CG: Recognition of thalido-mide defects. J. Med. Genet. (1992) 29:716–723.
   PubMed Web of Science ®Google Scholar
• VANCHIERI C: Preparing for thalidomide's comeback. Ann. Intern. Med. (1997) 127:951–952.
   PubMed Web of Science ®Google Scholar
• CLEMMENSEN 0J, OLSEN PZ, ANDERSEN KE: Thalido-mide neurotoxicity. Arch. Dermatol. (1984) 120:338–341.
   PubMed Web of Science ®Google Scholar
• WULFF CH, HOYER H, ASBOE-HANSEN G et al.: Develop-ment of polyneuropathy during thalidomide therapy. Br. J. Dermatol. (1985) 112:475–480.
   PubMed Web of Science ®Google Scholar
• OCHONISKT S, VERROUST J, BASTUJI-GARIN S et al Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch. Dermatol. (1994) 130:66–69.
   PubMedGoogle Scholar
• ARONSON IK, YU R, WEST DP et al.: Thalidomide-induced peripheral neuropathy. Arch. Dermatol. (1984) 120:1466–1470.
   PubMed Web of Science ®Google Scholar
• CALABRESE L, RESZTAK K: Thalidomide revisited: pharmacology and clinical applications. Exp. Opin. Invest. Drugs. (1998) 7(12):2043–2060.
   PubMedGoogle Scholar
• FULLERTON PM, O'SULLIVAN DJ: Thalidomide neuropathy: a clinical, electrophysiological and histological follow-up study. J. Neurol. Neurosurg. Psy. (1968) 31:543.
   PubMed Web of Science ®Google Scholar
• BONNETHLANE JM, ROYER C, BEDANE C: Thalidomideand recurrent aphthous stomatitis: a follow-up study. Dermatology (1996) 193:321–323.
   PubMed Web of Science ®Google Scholar
• HASLETT P, TRAMONTANA J, BURROUGHS M et al.: Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin. Infect. Dis. (1997) 24:1223–1227.
   PubMed Web of Science ®Google Scholar
• GARDNER-MEDWIN JMM, SMITH NJ, POWELL RJ: Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheum. Dis. (1994) 53:828–832.
   PubMed Web of Science ®Google Scholar
• ZELDIS JB, WILLIAMS BA, THOAMS SD et al.: S.T.E.P.S. ®: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. (1999) 21:319–330.
   Google Scholar